Sponsored

Meet Dr. Sharon Yavrom: Imugene’s (ASX:IMU) new Executive Director, Clinical Scientist

Image Source: Company Website

Highlights

  • Imugene has made a new addition to its management team.
  • The Company has appointed a highly skilled clinical scientist Dr. Sharon Yavrom as Executive Director, Clinical Scientist, effective 1 July 2022.
  • Yavrom has served as the clinical study lead for multiple clinical trials in the past.

Australia’s clinical stage immuno-oncology player, Imugene Limited (ASX:IMU), has appointed Dr. Sharon Yavrom as the Executive Director, Clinical Scientist. She has taken over the role with immediate effect from 1 July 2022.

Following the release of the announcement, Imugene’s share price rallied by over 8% to A$0.195 on 1 July 2022. The shares are now trading at A$0.202, as of 11:11 AM AEST.

Recently, Imugene appointed Dr. Yanghee Woo to its Scientific Advisory Board (SAB). Dr. Woo is a well-known surgeon-scientist, who holds deep clinical expertise in gastric cancer and robotic surgery.

About Dr. Yavrom

Dr. Sharon Yavrom is an accomplished clinical scientist, who holds about 20 years of industry experience in both emerging and established pharmaceutical companies. Previously, she has held positions at many industry-leading companies, including BMS, Amgen, and TAP Pharmaceuticals.

She has dedicated the last ten years of her career to working exclusively for start-up companies, with a focus on the oncology therapeutics space. These companies include Synta Pharmaceuticals, Tocagen, Aduro, Puma Biotechnology, MEI Pharma and Oncternal.

In terms of educational qualifications, Dr. Yavrom holds a Ph.D. degree in Pathobiology from the Keck School of Medicine of USC (University of Southern California). She also holds a Bachelor of Science (B.Sc.) degree in Biology from California-based San Jose State University.

Ideal addition to management team

Dr. Yavrom has served as the clinical study lead for multiple clinical trials. Moreover, she has immense experience with various tumour types, including NSCLC, HER2+ breast cancer, glioblastoma, colorectal cancer, non-invasive bladder cancer, Ewing’s Sarcoma, NHL and CLL.

Remarks by Imugene’s MD & CEO, Ms Leslie Chong:

Do Not Miss: What lies ahead for Imugene Limited (ASX:IMU) in 2022?


 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and